Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
47.78 SEK | +2.53% |
|
+15.39% | +84.27% |
05-31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
05-31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Analyst Reco.